Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

被引:0
|
作者
Wang, Yu-Qin [1 ]
Pan, Di [2 ]
Yao, Zhi-Yuan [2 ]
Li, Yu-Qi [2 ]
Qu, Peng-Fei [3 ]
Wang, Run-Bang [4 ]
Gu, Qing-Hao [4 ]
Jiang, Jie [5 ]
Han, Zheng-Xiang [2 ]
Liu, Hao-Nan [2 ]
机构
[1] Xuzhou Med Univ, Affiliated Hosp, Dept Gen Surg, Xuzhou 221000, Jiangsu Prov, Peoples R China
[2] Xuzhou Med Univ, Affiliated Hosp, Dept Oncol, 99 Huaihai West Rd, Xuzhou 221000, Jiangsu Prov, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Xuzhou 221000, Jiangsu Prov, Peoples R China
[4] Xuzhou Med Univ, Coll Clin Med 1, Xuzhou 221000, Jiangsu Prov, Peoples R China
[5] Suining Cty Peoples Hosp, Dept Oncol, Xuzhou 221000, Jiangsu Prov, Peoples R China
关键词
Hepatocellular carcinoma; Camrelizumab; Lenvatinib; Efficacy; Safety; US CHILDREN; SORAFENIB; ASSOCIATION; BEVACIZUMAB; ADOLESCENTS; PREVALENCE; OVERWEIGHT; THERAPY; OBESITY;
D O I
10.3748/wjg.v30.i37.4132
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Primary liver cancer is the sixth most common cancer worldwide, with hepatocellular carcinoma (HCC) being the most prevalent form. Despite the current availability of multiple immune or immune combination treatment options, the prognosis is still poor, so how to identify a more suitable population is extremely important. AIM To evaluate the clinical effectiveness of combining lenvatinib with camrelizumab for patients with hepatitis B virus (HBV)-related HCC in Barcelona Clinic Liver Cancer (BCLC) stages B/C, considering various body mass index (BMI) in different categories. METHODS Retrospective data were collected from 126 HCC patients treated with lenvatinib plus camrelizumab. Patients were divided into two groups based on BMI: The non-overweight group (BMI < 25 kg/m(2), n = 51) and the overweight/obese group (BMI >= 25 kg/m(2), n = 75). Short-term prognosis was evaluated using mRECIST criteria, with subgroup analyses for non-overweight (BMI: 18.5-24.9 kg/m(2)), overweight (BMI: 25-30 kg/m(2)), and obese (BMI >= 30 kg/m(2)) patients. A Cox proportional hazards regression analysis identified independent prognostic factors for overall survival (OS), leading to the development of a column-line graph model. RESULTS Median progression-free survival was significantly longer in the obese/overweight group compared to the non-overweight group. Similarly, the median OS was significantly prolonged in the obese/overweight group than in the non-overweight group. The objective remission rate and disease control rate for the two groups of patients were, respectively, objective remission rate (5.88% vs 28.00%) and disease control rate (39.22% vs 62.67%). Fatigue was more prevalent in the obese/overweight group, while other adverse effects showed no statistically significant differences (P > 0.05). Subgroup analysis based on BMI showed that obese and overweight patients had better progression-free survival and OS than non-overweight patients, with obese patients showing the best outcomes. Multifactorial regression analysis identified BCLC grade, alpha-fetoprotein level, portal vein tumor thrombosis, and BMI as independent prognostic factors for OS. The column-line graph model highlighted the importance of BMI as a major predictor of patient prognosis, followed by alpha-fetoprotein level, BCLC classification, and portal vein tumor thrombosis. CONCLUSION BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Body mass index: short- and long-term impact on kidney transplantation
    Orlic, L.
    Mikolasevic, I.
    Jakopcic, I.
    Grskovic, A.
    Pranjic, I. Jelic
    Racki, S.
    Stimac, D.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2015, 69 (11) : 1357 - 1365
  • [22] Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma
    Zhou, Cheng
    Zhang, Xin
    Zhou, Kaiqian
    Hou, Yingyong
    Chen, Feiyu
    Zhang, Xiangyu
    Ji, Yuan
    Qiu, Shuangjian
    Fan, Jia
    Zhou, Jian
    Zhou, Yuhong
    Wang, Zheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [23] Clinical Course and Prognosis of Long-Term Survivors of Hepatocellular Carcinoma
    Kim, Soon Sun
    Lee, Jonghyun
    Ahn, Sang Bong
    Chon, Young Eun
    Yoon, Eileen
    Jeong, Soung Won
    Jun, Dae Won
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025,
  • [24] Clinicopathologic Characteristics and Long-Term Prognosis of Scirrhous Hepatocellular Carcinoma
    Lee, Jin Hee
    Choi, Moon Seok
    Gwak, Geum Yeon
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    Yoo, Byung Chul
    Choi, Dongil
    Park, Cheol Keun
    DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (06) : 1698 - 1707
  • [25] Long-term Prognosis in Hepatocellular Carcinoma Patients after Hepatectomy
    Zhou, Lei
    Liu, Chang
    Meng, Fan-Di
    Qu, Kai
    Tian, Feng
    Tai, Ming-Hui
    Wei, Ji-Chao
    Wang, Rui-Tao
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (02) : 483 - 486
  • [26] LONG-TERM PROGNOSIS OF SURGICAL PATIENTS WITH HEPATOCELLULAR-CARCINOMA
    KAWANO, N
    OHMORI, Y
    INOUE, S
    NAGAO, T
    MORIOKA, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 : S129 - S132
  • [27] Long-term prognosis after resection of cryptogenic hepatocellular carcinoma
    Yu Ohkura
    Kazunari Sasaki
    Masamichi Matsuda
    Masaji Hashimoto
    Goro Watanabe
    BMC Surgery, 15
  • [28] Long-term prognosis after resection of cryptogenic hepatocellular carcinoma
    Ohkura, Yu
    Sasaki, Kazunari
    Matsuda, Masamichi
    Hashimoto, Masaji
    Watanabe, Goro
    BMC SURGERY, 2015, 15
  • [29] Clinicopathologic Characteristics and Long-Term Prognosis of Scirrhous Hepatocellular Carcinoma
    Jin Hee Lee
    Moon Seok Choi
    Geum Yeon Gwak
    Joon Hyeok Lee
    Kwang Cheol Koh
    Seung Woon Paik
    Byung Chul Yoo
    Dongil Choi
    Cheol Keun Park
    Digestive Diseases and Sciences, 2012, 57 : 1698 - 1707
  • [30] Impact of body mass index on postoperative complications and long-term survival in patients with esophageal squamous cell carcinoma
    Kamachi, Kenichi
    Ozawa, Soji
    Hayashi, Tsutomu
    Kazuno, Akihito
    Ito, Eisuke
    Chino, Osamu
    Shimada, Hideo
    Makuuchi, Hiroyasu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)